Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Hemostemix V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc is a clinical-stage biotechnology company. The company's principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions. Its technology platform for developing autologous cell therapies is for the treatment of vascular diseases. The group's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of critical limb ischemia.


Opinion & Analysis (TSXV:HEM)

    The Latest Biotech Investment Opportunity is the Next Generation of Regenerative Medicine

    Dave Jackson April 21, 2021

    Shaping the Future of Regenerative Medicine Today

    Dave Jackson February 11, 2021

    Hemostemix Founder: A Man with a Compassionate Heart

    Featured Submission December 15, 2020

    Shaping the Future of Medicine by Delivering Regenerative Medicines

    Dave Jackson December 9, 2020